熱門資訊> 正文
Ultragenyx Pharmaceutical定价3.5亿美元证券发行
2024-06-14 16:45
- Ultragenyx Pharmaceutical (NASDAQ:RARE) announces the pricing of its underwritten public offering of 7,435,898 shares of its common stock at $39.00 per share, and pre-funded warrants offering to purchase 1,538,501 shares of its common stock at a purchase price of $38.999 per pre-funded warrant, for expected gross proceeds of $350 million.
- In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,346,153 shares of the company's common stock at the public offering price.
- The offering is expected to close on or about June 17, 2024.
More on Ultragenyx Pharmaceutical
- Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
- Ultragenyx to file for accelerated approval of rare metabolic disease candidate
- Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
- Seeking Alpha’s Quant Rating on Ultragenyx Pharmaceutical
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
